Oncotarget

Research Papers:

An immunogenic NSCLC microenvironment is associated with favorable survival in lung adenocarcinoma

Kevin B. Givechian _, Chad Garner, Steve Benz, Bing Song, Shahrooz Rabizadeh and Patrick Soon-Shiong

PDF  |  Full Text  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2019; 10:1840-1849. https://doi.org/10.18632/oncotarget.26748

Metrics: PDF 876 views  |   Full Text 1111 views  |   ?  


Abstract

Kevin B. Givechian1, Chad Garner2, Steve Benz1, Bing Song1, Shahrooz Rabizadeh1,2 and Patrick Soon-Shiong1,2,3

1NantOmics LLC, Culver City, CA 90232, USA

2NantHealth, Inc. NantWorks, Culver City, CA 90232, USA

3NantBioscience, Inc. NantWorks, Culver City, CA 90232, USA

Correspondence to:

Kevin B. Givechian, email: Kevin.Givechian@nantomics.com

Keywords: NSCLC; lung adenocarcinoma; lung squamous cell carcinoma; tumor immunology; tumor microenvironment

Abbreviations: NSCLC: non-small cell lung cancer; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; OS: overall survival; TME: tumor microenvironment

Received: January 25, 2019     Accepted: February 15, 2019     Published: March 05, 2019

ABSTRACT

The tumor microenvironment consists of an intricately organized system through which immune cells and cancer cells may communicate to regulate anti-tumor immunogenicity. To this end, non-small cell lung cancer (NSCLC) has been shown to activate a variety of immunological mechanisms, thereby broadening our understanding of lung cancer immunobiology. However, while recent work has highlighted the importance of NSCLC immunology and prognosis, studies have not yet examined the tumor microenvironment (TME) globally in regards to the survival outcomes between two major NSCLC subtypes: lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). In the present study, we identify an immunogenic tumor microenvironment state in NSCLC that is enriched for the lung adenocarcinoma subtype. By utilizing TME cell enrichment scores and RNA-seq expression data, we show that the inflamed TME is associated with favorable patient survival in lung adenocarcinoma, but this does not hold true for lung squamous cell carcinoma. Moreover, differentially regulated pathways between immune-inflamed and immune-excluded tumors within LUAD and LUSC were not subtype specific. Instead, immune-inflamed LUSC samples possessed elevated immune checkpoint marker expression when compared to those of the LUAD samples, thereby offering a putative explanation for our prognostic observations. These results shed light on the immunological prognostic effects within lung cancer and may encourage further TME exploration between these two subtypes as the landscape of NSCLC therapy progresses.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26748